Our Team
Our Team and Advisory Board consist of Multi-Disciplinary professionals who have many years of experience with drug development and ALS Clinical Trials. These expertise enable us to move in a fast and efficient pace to achieve our goal
Core team
Alon Ben-Noon
Chief Executive Officer
Co-Founder and Chief Executive Officer.
Prior to the establishment of NeuroSense Therapeutics, Alon founded MediCan Consulting, a successful consultancy firm which worked and collaborated with many leading pharmaceutical R&D companies, including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx, NeuroDerm and others. The firm’s diligent employees were pioneers, who paved the way to more efficient and accurate work in the industry, mainly in small biotech companies, while coordinating Innovative Drug Development Programs, managing operational activities and involved in business development activities.
Alon holds an MBA and BSc in Industrial Engineering, both from Ben-Gurion University
Dr. Oron Yacoby-Zeevi
Chief Scientific Officer
Chief Scientific Officer responsible for pre-clinical studies, formulation development and company’s pipeline.
Prior to working at NeuroSense, Oron was CSO at NeuroDerm, responsible for the development of their unique formulation.
In the past, she also served as Chief Science Officer at Harlan Biotech Israel Ltd., and R&D team leader at Insight Biopharmaceuticals Ltd.
She has 20 years experience in leading research and development programs, and GLP compliant pre-clinical development of numerous small molecule drugs and biologics, in various indications, including CNS diseases.
She is the author of more than 15 patents.
DVM; The Hebrew University of Jerusalem. PhD in Microbiology and Immunology; Ben-Gurion University
Dr. Jeff Sterling
Head of CMC
CMC Leader, responsible for product and formulation development.
Dr. Sterling has over 38 years of experience in Research and Development at Teva Pharmaceuticals.
One of the inventors of Azilect ® (Parkinson’s).
Received Rothschild Prize for Innovation and Horev Prize for Excellence in Medicinal Chemistry.
Ph.D. in Chemistry; Johns Hopkins University
Avital Pushett
Head of ALS Clinical Program
Avital leads the ALS clinical program at NeuroSense Therapeutics.
Experienced in research in the stem cell field, involving molecular biology and tissue culture.
Avital is a certified CRA.
She has a personal interest in ALS drug development (lost her father to ALS).
BSc – Biology and Business Management, MSc – Biomedical Science; both from The Hebrew University
Board of Directors
Alon Ben-Noon
Chief Executive Officer
Co-Founder and Chief Executive Officer.
Prior to the establishment of NeuroSense Therapeutics, Alon founded MediCan Consulting, a successful consultancy firm which worked and collaborated with many leading pharmaceutical R&D companies, including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx, NeuroDerm and others. The firm’s diligent employees were pioneers, who paved the way to more efficient and accurate work in the industry, mainly in small biotech companies, while coordinating Innovative Drug Development Programs, managing operational activities and involved in business development activities.
Alon holds an MBA and BSc in Industrial Engineering, both from Ben-Gurion University
Prof. Itzhak Krinsky
Prof. (Emeritus) Itzhak Krinsky, Ph.D. worked at Teva for 12 years, and served asExecutive Vice President, Corporate Business Development, a member of the Teva Executive Committee, Chairman of Teva Japan, South Korea, and Head of Business Development Asia Pacific.
Prior to joining Teva, he held various senior positions in investment banks in New York City including with Bankers Trust, Deutsche Bank, and the Silverfern Group, Inc.
Before his career on Wall Street, Prof. Krinsky was a Professor of Finance & Business Economics at the Michael G. DeGroote School of Business, McMaster University, Ontario, Canada. He has published more than 80 articles in leading peer reviewed academic journals.
Prof. Krinsky currently serves as a director in several private and public companies. In 2014, he was named by SCRIP as one of the top 100 Global Leaders in the Pharmaceutical Industry.
Prof. Krinsky received Bachelor’s and Master’s degrees in Economics from Tel Aviv University, Israel and a Ph.D. in Economics from McMaster University in Canada
Dr. Oron Yacoby-Zeevi
Chief Scientific Officer
Chief Scientific Officer responsible for pre-clinical studies, formulation development and company’s pipeline.
Prior to working at NeuroSense, Oron was CSO at NeuroDerm, responsible for the development of their unique formulation.
In the past, she also served as Chief Science Officer at Harlan Biotech Israel Ltd., and R&D team leader at Insight Biopharmaceuticals Ltd.
She has 20 years experience in leading research and development programs, and GLP compliant pre-clinical development of numerous small molecule drugs and biologics, in various indications, including CNS diseases.
She is the author of more than 15 patents.
DVM; The Hebrew University of Jerusalem. PhD in Microbiology and Immunology; Ben-Gurion University
Gil Hakim
Gil Hakim is currently the Chairman and CEO of Armenta.
He has more than 20 years of experience in the biotech industry, including President of Israeli Operations at Urogen Pharma, CEO of Theracoat (Urogen Pharma), Director of New Product Development at Medispec, and more.
B.Sc. in Life Sciences from Ben-Gurion University
Amir Gross
Amir is currently the co-founder & managing partner of CardioValve.
He is also founder & former CEO of Valtech Cardio, which was sold for $1B.
Amir has over 15 years of leadership experience in the medical device industry.
He holds more than 40 patents and patent applications.
Amir holds a Bachelor of Law (LLB) and an MBA from Manchester University
Scientific Advisory Board
Prof. Jeremy Shefner
A leading Scientific Advisory Board member at NeuroSense Therapeutics.
Prof. Shefner is a Senior VP at the Barrow Neurological Institute and chair of the Department of Neurology.
In 1996 he co-founded the Northeast ALS Clinical Trials Consortium (NEALS).
He has as developed numerous outcome measures for clinical trials and is a member of the Editorial Boards of the ALS Journal and Neurotherapeutics.
Prof. Shefner is an MD with Distinction, Northwestern University Medical School ; PhD (sensory physiology), The University of Illinois
Dr. Ben-Zion Weiner
A Scientific Advisory Board member at NeuroSense Therapeutics.
During a 37-year-long career at Teva Pharmaceutical Industries Ltd, Dr. Ben-Zion Weiner held various senior research and development positions, including Senior Vice President of Global Research and Development.
He has received the Rothschild Prize for industrial innovation twice – for the development of copaxone for the treatment of multiple sclerosis, and alpha D3 for kidney and bone disorders.
PhD in Organic Chemistry ; The Hebrew University of Jerusalem. Postdoctoral Fellowship at Schering Plough, drug company in the US
Advisory Board
Dr. Shoshi Tessler
A senior member of NeuroSense Therapeutics Advisory Board.
Dr. Tessler has over 16 years of experience in leading projects from discovery to Phase III in various indications.
Currently a a VP R&D at Biosight Pharma.
Former VP R&D at Enzymotec and Project Champion at Teva Pharmaceutical Innovative R&D.
PhD in Biology from the Technion-Israel Institute of Technology and Postdoctoral Fellowship, Babraham Inst, Cambridge UK in the field of glutamate transporters and neurological diseases
Dr. Revital Mandil-Levin
An Advisory Board member at NeuroSense Therapeutics.
Dr. Revital Mandil-Levin is a biotech executive with more than 15 years’ of experience in product and business development in the pharmaceutical industry, ranging from early stages startups to mature clinical stage pharmaceutical companies. She has previously served as Chief Business Development Officer at CollPlant Holdings Ltd, and as Vice President Corporate Development at NeuroDerm Ltd. (acquired by Mitsubishi Tanabe for $1.1 billion).
Dr. Mandil-Levin holds a PhD in Biochemistry from Bar-Ilan University, Israel, and an MBA from the Israeli College of Management School of Business.
Dr. Yossi Gilgun-Sherki
An Advisory Board member at NeuroSense Therapeutics.
Dr. Yossi Gilgun-Sherki has more than 20 years of experience in academic research & the pharmaceutical industry. Some of his previous positions include Head of Specialty Products at Dexcel Pharma and Global Clinical Program Leader & Senior Clinical Scientist at Teva Global Innovative R&D group.
Dr. Gilgun-Sherki has previously served as an investigator and coordinator in clinical trials conducted at the Neurology Department, Rabin Medical Center.
He is a (co)author of over 40 publications and book chapters, and an inventor of 6 patents in the field of neurodegeneration.
Dr. Gilgun-Sherki holds a PhD degree from the Sackler Faculty of Medicine, Tel Aviv University, in neuropharmacology, and an MBA degree from The Open University of Israel.
Dr. Nili Schutz
An Advisory Board member at NeuroSense Therapeutics.
Dr. Schutz is the CEO of Heparx – a Biotech company.
She is a Medicinal Chemistry professional with over 10 years of leadership experience in pharmaceutical drug discovery & development (EPIX, Dynamix), and experience in collaboration with big pharma companies.
PhD from USC (LA, USA) under the supervision of Arieh Warshel (Nobel Prize in Computational Chemistry) ; Bio-MBA from the Israeli College of Management
In Memoriam
Shay Rishoni
Shay began serving as an Advisory Board member in 2016. He passed away on May 24th 2018.
Shay was a Chairman and former CEO at Prize4Life, a non-profit organization dedicated to accelerating the discovery of treatments and a cure for ALS.
Received the President’s medal for volunteer in 2016.
Shay held an MBA from the University of Hartford
Shay was a truly inspiring and optimistic man, who didn’t let his disease stop him from doing amazing work for the ALS community.
We are honored to have known him and worked with him.
He leaves us with an immense legacy.
